Key facts
- Neok Bio’s last known valuation is $116.5M (Mar 2026).
- It has raised $75.0M; the latest was Early Stage VC ($75.0M) in Mar 2026.
- Notable investors include ABL Bio.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Neok Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Neok Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neok Bio
Operator of biotechnology research and development intended to transform the treatment of cancer by solving therapeutic challenges and improving patient outcomes. The company offers differentiated bispecific Antibody Drug Conjugates that utilize a dual-targeting strategy, enabling customers to treat solid tumors with unmet needs through improved safety and efficacy, paving the way for a new era of precision medicine.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2025
- Website
- neokbio.com/
- Ownership
- Privately Held (backing)
Neok Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neok Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neok Bio in its N-PORT filings yet. We sweep new filings monthly.